Revolutionary Blood Test for Early Cancer Detection Launched in India

Zydus Lifesciences and Apollo Hospitals have launched the Shield Multi-Cancer Detection test, a revolutionary blood test that screens for signals of ten common cancers from a single sample. Aimed at adults over 45, this test utilizes advanced genomic technology to identify potential cancer presence and the originating organ. While it offers a less invasive alternative to traditional screening methods, experts caution that it should not replace standard tests. With over 1.41 million new cancer cases reported in India in 2022, this innovative approach could significantly enhance early detection, especially for cancers lacking organized screening programs. However, further studies are needed to evaluate its long-term effectiveness and cost-efficiency.

By Narendra Chaudhary Jul 4, 2026, 11:34 IST

Introduction to a New Cancer Screening Method

Cancer continues to pose a significant health threat in India, with many individuals receiving diagnoses only after symptoms manifest, complicating treatment options. In a groundbreaking initiative aimed at enhancing early detection, Zydus Lifesciences from Ahmedabad has teamed up with Apollo Hospitals to launch the Shield Multi-Cancer Detection (MCD) test. This innovative blood test can identify signals linked to ten prevalent cancers from a single blood sample. Developed by Guardant Health, a precision oncology firm based in the United States, this marks the introduction of multi-cancer early detection (MCED) technology in India. While experts are optimistic about its potential to revolutionize cancer screening, they caution that it should not replace traditional screening methods or serve as a diagnostic tool.

Understanding the Shield Multi-Cancer Detection Test

What is the Shield Multi-Cancer Detection test?

The Shield MCD test is intended for adults aged 45 and older who are at average risk for cancer. Unlike traditional tests that focus on a single type of cancer, this test examines methylation patterns—chemical alterations in small DNA fragments released into the bloodstream by cancer cells. Utilizing cutting-edge genomic technology and artificial intelligence, it detects abnormal DNA signals that may indicate cancer presence and often suggests the originating organ. The test screens for various cancers, including breast, lung, colorectal, liver, pancreatic, ovarian, prostate, bladder, gastric, and esophageal cancers, many of which are leading causes of cancer-related deaths in India due to late-stage detection.

Comparison with Traditional Screening Methods

How is it different from traditional cancer screening?

Traditional screening techniques typically target one cancer at a time. For instance:

Mammography is used for breast cancer detection.

Colonoscopy is employed to identify colorectal cancer.

Pap smears are conducted for cervical cancer screening.

Low-dose CT scans are utilized for lung cancer detection in high-risk groups.

The new blood test aims to detect signals from multiple cancers at once, offering a less invasive and potentially more convenient screening option. However, medical professionals stress that a positive result does not confirm cancer; it indicates the need for further investigations, such as imaging scans, endoscopy, or biopsies. Similarly, a negative result does not entirely exclude the possibility of cancer, underscoring the importance of continuing routine screenings and medical assessments as advised.

Significance of the Test for India

Why this could be important for India?

In 2022, India reported over 1.41 million new cancer cases, with more than 900,000 deaths attributed to the disease. The lack of organized screening programs means many patients are diagnosed only after symptoms arise. MCED blood tests could be particularly beneficial for cancers that currently do not have standard population-wide screening protocols, such as pancreatic, liver, stomach, and ovarian cancers. Interest in multi-cancer blood tests is on the rise globally. A significant study involving over 84,000 participants across six Asian nations found that the MCED blood test accurately detected approximately 79% of confirmed cancers while identifying individuals without cancer in 99.9% of cases. Researchers also noted that the test successfully predicted the likely organ of origin in nearly 80% of confirmed cases, aiding doctors in determining subsequent diagnostic steps. Experts view these results as promising, especially for low- and middle-income countries where organized cancer screening is limited. However, ongoing long-term studies are necessary to assess whether widespread adoption of MCED tests will ultimately lower cancer mortality rates and their cost-effectiveness.

Caution from Experts

Experts urge caution

Cancer researchers emphasize that while the technology shows great promise, it should be regarded as an additional screening tool rather than a definitive diagnostic method. Medical professionals highlight the importance of developing similar technologies tailored to India's genetically diverse population in the future. The pricing for the Shield MCD test in India has yet to be disclosed, but it is anticipated to be available through Apollo Hospitals, with indications that Dr. Dang's Lab may also provide the test nationwide.